Drug Profile
Research programme: antibacterial ribosomal protein inhibitors - BioVersys
Alternative Names: BV-300; RX 01413; RX 01423; RX 01445; RX-01; RX-01(a); RX-01(b); RX-01_413; RX-01_423; RX-01_445; RX-02; RX-03; RX-04; RX-04A; RX-04B; RX-04C; RX-04D; RX-05; RX-230; RX-5312; RX-6425; RX-6567; RX-P2177; RX-P2382; RX-P770; RX-P873Latest Information Update: 03 Jun 2021
Price :
$50
*
At a glance
- Originator Rib-X Pharmaceuticals
- Developer BioVersys; Melinta Therapeutics
- Class Antibacterials; Pyrimidines; Pyrroles; Small molecules
- Mechanism of Action Protein 50S ribosomal subunit inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Bacterial infections
Most Recent Events
- 03 Jun 2021 Research programme: antibacterial ribosomal protein inhibitors - BioVersys is available for licensing as of 03 Jun 2021. https://bioversys.com/partners/
- 03 Jun 2021 Preclinical development in Bacterial infections in Switzerland (unspecified route)
- 01 Jun 2021 Discontinued - Preclinical for Bacterial infections in USA (PO)